Breast-conserving surgeries in HER-positive breast cancer patients are performed too rarely in Poland by Kufel-Grabowska, Joanna et al.
225
Original article
NOWOTWORY Journal of Oncology 
2020, volume 70, number 6, 225–229
DOI: 10.5603/NJO.2020.0047
© Polskie Towarzystwo Onkologiczne
ISSN 0029–540X
www.nowotwory.edu.pl
Breast-conserving surgeries in HER-positive breast cancer 
patients are performed too rarely in Poland
Joanna Kufel-Grabowska1, 2, Barbara Radecka3, 4, Joanna Streb5, Agnieszka Jagiełło-Gruszfeld6, 
Joanna Hudała-Klecha4, Ewa Szombara6, Renata Sienkiewicz6,  
Bogumiła Czartoryska-Arłukowicz7, Piotr Witasik8, Katarzyna Sokołowska9, Wojciech M. Wysocki10, 11, 12
1Department and Chair of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland
2Chemotherapy Department, Greater Poland Cancer Centre, Poznan, Poland
3Department of Oncology, Institute of Medical Sciences, University of Opole, Poland
4Department of Clinical Oncology, Tadeusz Koszarowski Cancer Center in Opole, Opole, Poland
5Oncology Clinical Department, Krakow University Hospital , Krakow, Poland
6Breast Cancer and Reconstruction Surgery Clinic, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
7Clinical Oncology Department with Outpatient Chemotherapy Sub-department of the Maria Skłodowska-Curie Bialystok Oncology Centre, Bialystok, 
Poland  
8Oncology Department with Haematology Sub-department, Dr Roman Ostrzycki Voivodeship Hospital in Konin, Poland 
9Roche Polska Sp. z o. o.
10General, Oncological and Vascular Surgery Clinic, 5th Military Hospital with a Polyclinic, Krakow, Poland
11Chair of Surgery, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University , Krakow, Poland
12Scientific Editors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
 Breast cancer is the most common cancer among women in Poland and worldwide; after lung cancer it is the second 
highest cause of death among females with malignancies. HER2 positive breast cancer occurs in ca.15–20% of all cases. 
More often than other subtypes, it affects younger patients and more often spreads metastasises to internal organs. The 
new drugs against the HER2 receptor significantly improve patients’ prognoses, regardless of the initial stage.
 The authors of the study involved 1503 patients with HER2 positive breast cancer from all stages (I–IV); 482 patients received 
preoperative systemic therapy (chemotherapy or hormonal therapy), 385 trastuzumab. Among the 1219 females qualified 
to surgery, 734 (60%) underwent a mastectomy, 485 (40%) had breast conserving therapy with adjuvant radiotherapy, 
some of them had preoperative systemic treatment.
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Introduction
Breast cancer is the most commonly diagnosed cancer in 
women in Poland and worldwide. It is the second (after lung 
cancer) most common cause of cancer mortality. The prognosis 
depends, among other things, on the stage of the disease 
at the time of diagnosis, the biological subtype of cancer, 
the general clinical status of the patient, as well as access to 
different types of therapy [1]. 
Approximately 15–20% of all cases are HER2-positive can-
cers, overexpressing the HER2 receptor or amplifying the gene 
coding for this receptor protein. Compared to other subtypes, 
this biological subtype is diagnosed more commonly in young 
226
patients. The average age of diagnosis is approx. 50 years, so it 
is clearly lower than in the general breast cancer population. 
The predominant location of distant metastases in HER2-po-
sitive breast cancer is the liver and central nervous system [2]. 
Over the past few years, new HER2 inhibitors have significantly 
improved the efficacy of treatment of both early and advanced 
forms of the disease. The therapy now considered most active is 
the dual blockade of pertuzumab and trastuzumab, anti-HER2 
monoclonal antibodies, combined with chemotherapy. This is 
the standard in preoperative care for HER2-positive breast can-
cer patients with a primary tumour diameter exceeding 2 cm 
or with metastases to axillary lymph nodes. The prognosis of 
patients is improved when a complete pathological response 
(i.e. the absence of invasive cancer cells in the post-operative 
specimen) is achieved as a result of preoperative treatment 
[3]. Effective neoadjuvant therapy increases the likelihood of 
breast-conserving therapy.
A question arises as to whether the increasing effecti-
veness of preoperative treatment, leading to downsizing of 
the primary tumour and downstaging of the tumour status, 
entails a real change in the proportion of breast cancer pa-
tients treated with conserving therapy in Poland. Therefore, 
this article presents data on the type of breast surgeries 
performed in HER2-positive breast cancer patients treated 
in selected national cancer centres between January 2014 
and July 2017.
Material and methods
The study analysed retrospectively collected clinical data 
from 1503 HER2-positive breast cancer patients treated across 
7  Polish cancer centres (Wielkopolskie Centrum Onkologii 
[Greater Poland Cancer Centre], Centrum Onkologii w War-
szawie [Maria Sklodowska-Curie National Research Institute of 
Oncology in Warsaw], Białostockie Centrum Onkologii [Biały-
stok Oncology Centre], Mazowiecki Szpital Onkologiczny Wie-
liszew [Masovian Oncological Hospital in Wieliszew], Opolskie 
Centrum Onkologii [Opole Oncology Centre], Oddział Onkolo-
giczny  z  Pododdziałem Hematologicznym Wojewódzkiego 
Szpitala Zespolonego w Koninie [Department of Oncology with 
the Hematology Section at the Regional Polyclinical Hospital in 
Konin], Szpital Uniwersytecki w Krakowie [Krakow University 
Hospital]) between January 2014 and July 2017. The doctors 
from the centres completed a questionnaire prepared and 
distributed by Roche, which included age as a categorised 
value (<40 years of age, 41–50, 51–65, 66–75, >75 years of 
age), patients’ body weight, stage of the disease at the time 
of cancer diagnosis, and course of treatment including type of 
systemic treatment, surgery and adjunctive radiation therapy. 
All patient data was anonymous and gathered collectively, 
i.e. the responders stated how many patients in each centre 
meet the criteria of each question in the questionnaire. This 
method of data collection prevents tracking of the individual 
patients’ survival status.
The questionnaire also asked the participating doctors 
for their opinion about potential qualification for therapies 
not reimbursed in Poland at the time concerned, provided 
that such therapies were feasible in specific patients. These 
therapies were meant to include the combination of trastu-
zumab and pertuzumab in preoperative treatment and in 
treatment of generalised disease, as well as the combination 
of trastuzumab and emtansine in the treatment of advanced 
breast cancer. This paper selectively presents the results of an 
analysis of data concerning the surgical treatment method. 
All patients enrolled in the study were more than 18 years 
old and they were of good performance status (i.e. ECOG 0–2, 
Eastern Cooperative Oncology Group). 
Results
More than ¾ of the study group were over 65 years of age, 
which is typical of the HER2-positive breast cancer population. 
The age structure of the study group is presented in figures 
1 and 2.
The majority of the study group were patients with early 
breast cancer, accounting for 68% of the total group (331 
patients with TNM stage I and 688 patients with TNM stage II, 
representing 22% and 46% of the total group, respectively). 327 
patients (22%) had been diagnosed with stage III cancer, and 
157 patients (10%) had been diagnosed with stage IV cancer. 
(tab. I). In the group of women with distant metastases at study 
entry, the majority (62%, n = 98) were patients with primarily 









146 283 606 293 72
<40 years  41–50 years 51–65 years 65–75 years >75 years
kategorie wiekowe, dane dla 1400 chorych
≤65 years n = 1035 >66 years n = 365
Figure 1. Classification of patients by the presented age categories, data 
for 1400 patients
Figure 2. Classification of patients by two age categories, data for 1400 
patients
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of the disease after radical treatment. For the last mentioned 
subgroup of patients, the baseline advancement stage was 
unknown; therefore, the analysis classified them as stage IV.
Part of the patients (n = 482) received preoperative syste-
mic treatment: chemotherapy, hormone therapy and trastu-
zumab therapy. Chemotherapy was used in more than half 
of the patients, and the proportion of patients treated in this 
way was higher in the stage III group than in the stage II group 
(68% and 50%, respectively). Trastuzumab was used in appro-
ximately 60% of patients, and its use was equally common in 
stage II and III patients.
Of all patients qualified for primary surgery or for syste-
mic treatment followed by surgery (1219 patients in total), 
734 (60%) underwent a mastectomy and 485 (40%) received 
conserving therapy (fig. 3).
In the group of patients who underwent preoperative sys-
temic treatment (n = 413), mastectomy was significantly more 
common in patients with a higher stage of disease at baseline. 
In stage II patients (n = 174), mastectomy was performed in 
59% of the cases (n = 102) and conserving therapy was used in 
41% of the cases (n = 72); whereas in stage III patients (n = 239), 
these methods of treatment were used in 83% (n = 199) and 
17% (n = 40) of the cases, respectively (fig. 4). More than half 
of the patients (54%, n = 806) underwent primary surgical tre-
atment. These were exclusively patients diagnosed with stage 
I and II of the disease. Also in this group, mastectomies was 
performed more frequently than breast-conserving therapy 
(54%, n = 433 and 46%, n = 373, respectively).
Discussion
Having analysed the data presented above, it should first be 
noted that the proportion of advanced cases of the disease is 
not as high as mentioned before in the report from the Polish 
Society for Research on Breast Cancer, where it was claimed 
to exceed 50% [4]. In contrast, the analysed material, involving 
a total of >1500 patients, showed that 2/3 of patients were 
diagnosed with stage I and II disease (1019 patients in total). 
Therefore, it could be expected that the proportion of patients 
receiving conserving therapy would be high in this group. 
That said, conserving therapy was performed in only 40% of 
patients out of 1219 patients qualified for surgery. It is worth 
highlighting, however, that conserving therapy was more 
common in patients with lower stages of the disease. Because 
the data was gathered collectively and analysed as a whole, 
individual patients’ survival status could not be tracked. Since 
the questionnaire did not provide details about surgical qu-
alification, it was not possible to determine the reasons for 
the relatively low proportion of patients who had conserving 
therapy administered. This proportion differs significantly from 
the level of 60–80% which is recommended by international 
scientific societies [5, 6]. 
However, the proportion of patients treated with a breast-
-conserving approach should not be indiscriminately accepted 
as an independent indicator of the quality of treatment of 
Table I. Patient classification by breast cancer advancement stage (TNM), 
n = 1503 (100%)























































mastectomy; n = 734
breast conserving treatment; n = 485













1 – patients with stage II receiving preoperative treatment n = 174
2 – patients with stage III receiving preoperative treatment n = 239




Figure 4. Surgical treatment methods according to advancement stage 
at baseline and preoperative systemic treatment, n = 1219
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breast cancer patients in Poland. Current analysis from Australia 
and New Zealand indicates that  in these countries also, where 
a modern and efficient healthcare system is implemented, the 
recommended values of the indicator mentioned above or 
other similar quality measures are not universally met and are 
often below the desired levels [7]. However, notwithstanding 
this observation, reference should be made to last year’s ESMO 
recommendations, which clearly state that ‘breast-conserving 
surgery is the primary surgical choice for breast cancer’ [6]. In 
Poland, as indicated by the presented results, the proportion 
of breast-conserving procedures is still relatively low, despite 
the fact that in 2/3 of patients, the disease was diagnosed early. 
Nonetheless, the observed proportion of conserving pro-
cedures, although not satisfactory, is twice as high as that 
observed in previous years. Data from 2005 to 2007 indicates 
that breast-conserving therapy was used in Poland at that time 
in approx. 21% of cases (with geographical variation ranging 
from 10% to 30%) [8]. From this perspective, significant pro-
gress can be observed.
It should also be noted that in the study period, the pre-
operative targeted therapy was not used in HER2-positive 
breast cancer patients in Poland. On 1 January 2017, this type of 
therapy started to be reimbursed from public funds under the 
drug programme of the National Health Fund. Since that time, 
trastuzumab combined with chemotherapy could be used in 
HER2-positive breast cancer patients if the size of the primary 
tumour was at least 2 cm or there were metastases to axillary 
lymph nodes. Since only a few months ago, the combination 
of trastuzumab and pertuzumab plus chemotherapy has been 
reimbursed, which is the combination recommended for neo-
adjuvant treatment of HER2-positive breast cancer by both the 
European and American oncology societies [6]. Before that 
time in Poland, patients received HER2 antibodies only after 
surgery, and if initial systemic treatment was required due to 
high stage at baseline, only chemotherapy was administered. 
It is possible that these limitations might have played a part in 
the reduced efficacy of preoperative treatment and might have 
resulted in  higher incidences of mastectomy, although this 
is merely a hypothesis. Meta-analysis of 5 randomised clinical 
trials showed that the addition of trastuzumab to preoperative 
chemotherapy increased the likelihood of achieving a com-
plete pathological response without increasing treatment 
toxicity; however this did not translate into reduced incidence 
of mastectomy [9].
The efficacy of treatment in breast cancer patients de-
pends on, among other things, a well-organised and properly 
functioning breast cancer unit (BCU), and a structure which 
unites specialists across multiple diagnostic, treatment and 
broad patient care (psychological support, rehabilitation) 
fields. In Poland, the first accredited BCU was established in 
Szczecin in 2013, the second – in Kielce in 2015, and since 
2017, the Senologic International Society has accredited 5 
further units: Bydgoszcz (2017), Krakow (2017), Gdynia (2018), 
Warsaw (2018) and Opole (2019). The improved quality and 
efficacy of diagnostics and treatment within a BCU is linked to 
the close cooperation between specialists in different fields, 
who make collaborative decisions about different stages of 
patient management. Year-on-year, there is a growing num-
ber of accredited units that declare to perform at least 70% 
of breast-conserving surgeries in cancer patients. In recent 
years, BCUs in Poland have seen significant improvement in 
the availability and quality of oncoplastic procedures. Active 
units are subject to regular evaluation and, once specific criteria 
are met, reaccreditation.
   In recent years, many European countries have seen 
a desired trend towards an increased number of conserving 
surgeries at the expense of mastectomies. Between 2005 and 
2010, the number of mastectomies was observed to decrease 
by approximately 4% a year, whereas the average proportion 
of conserving surgeries accounted for 73% of the observed 
total surgeries. A different trend is observed in the USA, where 
the number of bilateral mastectomies increases – especially 
among younger patients, and the number of breast-conse-
rving surgeries decreases, whereas the proportion of unilateral 
mastectomies remains stable. This phenomenon can be expla-
ined by, among other things, the increased popularity and 
availability of genetic tests and bilateral mastectomies being 
performed in breast cancer patients who are known carriers 
of BRCA1/2 germinal mutations. It is also often mentioned 
that patients’ preference to undergo a bilateral mastectomy 
is attributed to a sense of increased safety after both bre-
asts are removed. Such a perception is quite common, as is 
the perception of greater efficacy of unilateral mastectomy 
compared to surgery that conserves the breast. It should be 
noted, however, that prognosis after conserving surgeries and 
mastectomy is comparable due to the increasing efficacy of 
adjuvant treatment [10]. In this context, it is extremely impor-
tant that patients must be thoroughly informed about the 
benefits and possible complications of different procedures. 
The misconception among women that mastectomy is a less 
risky procedure compared to conserving therapy is alarming; it 
indicates the need to properly educate and inform the patient 
during the informed consent process.
In everyday practice, validated questionnaires, completed 
by patients before and after surgery (e.g. BREAST Q), may be 
helpful and provide a valuable source of information on the 
patient’s motivation when selecting the type of surgery, as 
well as their level of satisfaction after surgery. Conclusions 
from the analysis of such data should be discussed by the 
entire team involved in the treatment and rehabilitation of 
breast cancer patients.
An increase in the number of breast-conserving surgeries 
depends, among others, on the stage of the disease, systemic 
treatment, and the availability of oncoplastic procedures car-
ried out by highly qualified surgeons. In HER2-positive breast 
cancer patients, the addition of pertuzumab to chemotherapy 
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and trastuzumab has increased the proportion of complete 
pathological responses, making neoadjuvant treatment more 
effective [3]. The dual HER2 blockade has been reimbursed in 
Poland since 2019, and, consequently, it would be desirable 
to conduct studies into investigating the types of surgeries 
selected by patients and surgeons. 
Conclusions
The presented data shows that the proportion of breast cancer 
patients treated with breast-conserving therapy is still relatively 
low in Poland. Breast-conserving procedures are performed in 
approx. 40% of patients and the data is mainly derived from 
referencing oncology centres. However, this proportion is twice 
as high as it was in the last decade. 
The introduction of preoperative systemic therapy targe-
ted at the HER receptor may significantly increase the incidence 
of breast-conserving procedures. Key importance is attached 
to interdisciplinary collaboration between BCUs and taking 
the utmost care when informing patients about their planned 
treatment.
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